Health-related quality of life in patients receiving oral anti-coagulants: a cross-sectional study

References

• Burn J, Pirmohamed M. Direct oral anticoagulants versus warfarin: is new always better than the old? Open Heart. 2018;5:e000712.
   PubMed Web of Science ®Google Scholar
• Wadhera RK, Russell CE, Piazza G. Cardiology patient page. Warfarin versus novel oral anticoagulants: how to choose? Circulation. 2014;130:e191–3.
   PubMedGoogle Scholar
• Barnes GD, Lucas E, Alexander GC, et al. National trends in ambulatory oral anticoagulant use. Am J Med. 2015;128:1300–5.e2.
   PubMed Web of Science ®Google Scholar
• Mosteller F, Falotico-Taylor J, editors; Institute of Medicine (US) Council on Health Care Technology. Quality of life and technology assessment: monograph of the council on health care technology. In: Assessing quality of life: measures and utility. Washington (DC): National Academies Press (US); 1989. p. 6. Available from: https://www.ncbi.nlm.nih.gov/books/NBK235120/
   Google Scholar
• Devlin NJ, Brooks R. EQ-5D and the EuroQol group: past, present and future. Appl Health Econ Health Policy. 2017;15:127–137.
   PubMed Web of Science ®Google Scholar
• Burckhardt CS, Anderson KL. The quality of life scale (QOLS): reliability, validity, and utilization. Health Qual Life Outcomes. 2003;1:60.
   PubMedGoogle Scholar
• Prins MH, Guillemin I, Gilet H, et al. Scoring and psychometric validation of the perception of anticoagulant treatment questionnaire (PACT-Q). Health Qual Life Outcomes. 2009;7:30.
   PubMed Web of Science ®Google Scholar
• Diana M-P, Consuelo R-A, Paz A-M, et al. Analysis of general and oral quality of life and satisfaction with treatment among anticoagulated patients. J Dent Oral Health. 2015;1:1–4.
   Google Scholar
• Benzimra M, Bonnamour B, Duracinsky M, et al. Real-life experience of quality of life, treatment satisfaction, and adherence in patients receiving oral anticoagulants for atrial fibrillation. Patient Prefer Adherence. 2018;12:79–87.
   PubMed Web of Science ®Google Scholar
• Monz BU, Connolly SJ, Korhonen M, et al. Assessing the impact of dabigatran and warfarin on health-related quality of life: results from an RE-LY sub-study. Int J Cardiol. 2013;168:2540–2547.
   PubMed Web of Science ®Google Scholar
• Alegret JM, Viñolas X, Arias MA, et al. New oral anticoagulants vs vitamin K antagonists: benefits for health-related quality of life in patients with atrial fibrillation. Int J Med Sci. 2014;11:680–684.
   PubMed Web of Science ®Google Scholar
• Riva N, Borg Xuereb C, Makris M, et al. Reliability and validity of the maltese version of the perception of anticoagulant treatment questionnaire (PACT-Q). Patient Prefer Adherence. 2019;13:969–979.
   PubMed Web of Science ®Google Scholar
• Prins MH, Marrel A, Carita P, et al. Multinational development of a questionnaire assessing patient satisfaction with anticoagulant treatment. Health Qual Life Outcomes. 2009;7:9.
   PubMed Web of Science ®Google Scholar
• Janežič A, Locatelli I, Kos M. Criterion validity of 8-item Morisky medication adherence scale in patients with asthma. PLoS One. 2017;12:e0187835.
   PubMed Web of Science ®Google Scholar
• Gateman D, Trojnar ME, Agarwal G. Time in therapeutic range: warfarin anticoagulation for atrial fibrillation in a community-based practice. Can Fam Physician. 2017;63:e425–e431.
   PubMed Web of Science ®Google Scholar
• Keita I, Aubin-Auger I, Lalanne C, et al. Assessment of quality of life, satisfaction with anticoagulation therapy, and adherence to treatment in patients receiving long-course vitamin K antagonists or direct oral anticoagulants for venous thromboembolism. Patient Prefer Adherence. 2017;11:1625–1634.
   PubMed Web of Science ®Google Scholar
• Okello S, Nasasira B, Muiru AN, et al. Validity and reliability of a self-reported measure of antihypertensive medication adherence in Uganda. PLoS One. 2016;11(7):e0158499.
   PubMed Web of Science ®Google Scholar
• Balcı KG, Balcı MM, Canpolat U, et al. Comparison of health-related quality of life among patients using novel oral anticoagulants or warfarin for non-valvular atrial fibrillation. Anatol J Cardiol. 2016;16:474–481.
   PubMed Web of Science ®Google Scholar
• Cosansu K, Ureyen CM, Yılmaz S. Effect of novel oral anticoagulants on hospital anxiety and depression scale scores. Herz. 2019 Jun 24. DOI:10.1007/s00059-019-4828-1.
   PubMed Web of Science ®Google Scholar
• Zubaid M, Rashed WA, Alsheikh-Ali AA. et al.; Gulf Survey of Atrial Fibrillation Events (Gulf SAFE) Investigators. Management and 1-year outcomes of patients with atrial fibrillation in the Middle East: gulf survey of atrial fibrillation events. Angiology. 2015;66:464–471
   PubMed Web of Science ®Google Scholar
• Piccini JP, Hernandez AF, Zhao X, et al. Get with the guidelines steering committee and hospitals. Quality of care for atrial fibrillation among patients hospitalized for heart failure. J Am Coll Cardiol. 2009;54:1280–1289.
   PubMed Web of Science ®Google Scholar
• Lip GY, Laroche C, Dan GA, et al. ‘Real-world’ antithrombotic treatment in atrial fibrillation: the EORP-AF pilot survey. Am J Med. 2014;127:519–29.e1.
   PubMed Web of Science ®Google Scholar
• Lane DA, Lip GY. Barriers to anticoagulation in patients with atrial fibrillation: changing physician-related factors. Stroke. 2008;39:7–9.
   PubMed Web of Science ®Google Scholar
• Alonso-Coello P, Montori VM, Díaz MG, et al. Values and preferences for oral antithrombotic therapy in patients with atrial fibrillation: physician and patient perspectives. Health Expect. 2015;18:2318–2327.
   PubMed Web of Science ®Google Scholar
• Crivera C, Nelson WW, Schein JR, et al. Attitudes toward anticoagulant treatment among nonvalvular atrial fibrillation patients at high risk of stroke and low risk of bleed. Patient Prefer Adherence. 2016;10:795–805.
   PubMed Web of Science ®Google Scholar
• Pozzi M, Mitchell J, Henaine AM, et al. International normalized ratio self-testing and self-management: improving patient outcomes. Vasc Health Risk Manag. 2016;12:387–392.
   PubMed Web of Science ®Google Scholar
• Dean C, O’Leary K, Platt AB, et al. Improving patient adherence to warfarin therapy. J Clin Outcomes Manag. 2010;17:27–32.
   Google Scholar
• Kooistra HA, Piersma-Wichers M, Kluin-Nelemans HC, et al. Impact of vitamin K antagonists on quality of life in a prospective cohort of 807 atrial fibrillation patients. Circ Cardiovasc Qual Outcomes. 2016;9:388–394.
   PubMed Web of Science ®Google Scholar
• Maura G, Billionnet C, Alla F, et al. Comparison of treatment persistence with dabigatran or rivaroxaban versus vitamin K antagonist oral anticoagulants in atrial fibrillation patients: a competing risk analysis in theFrench national health care databases. Pharmacotherapy. 2018;38(1):6–18.
   PubMed Web of Science ®Google Scholar
• Maura G, Pariente A, Alla FB, et al. Adherence with direct oral anticoagulants in non valvular atrial fibrillation new users and associated factors: a French nationwide cohort study. Pharmacoepidemiol Drug Saf. 2017;26:1367–1377.
   PubMed Web of Science ®Google Scholar
• Johnson ME, Lefèvre C, Collings SL, et al. Early real-world evidence of persistence on oral anticoagulants for stroke prevention in non-valvular atrial fibrillation: a cohort study in UK primary care. BMJ Open. 2016;6:e011471.
   PubMed Web of Science ®Google Scholar
• Andrade JG, Krahn AD, Skanes AC, et al. Values and preferences of physicians and patients with non valvular atrial fibrillation who receive oral anticoagulation therapy for stroke prevention. Can J Cardiol. 2016;32:747–753.
   PubMed Web of Science ®Google Scholar
• Zolfaghari S, Harenberg J, Froelich L, et al. Development of a tool to identify patients’ preference for vitamin K antagonist or direct oral anticoagulant therapy. Semin Thromb Hemost. 2014;40:121–128.
   PubMed Web of Science ®Google Scholar